Endokrinologische Nebenwirkungen einer onkologischen Therapie mit Anti-CTLA-4-Antikörpern

Zusammenfassung

Neue immunmodulierende Therapien wie monoklonale Anti-CTLA-4-Antikörper werden zunehmend als onkologische Therapien eingesetzt. Gut untersucht und dokumentiert ist Ipilimumab, zur Behandlung des metastasierten Melanoms, das jedoch auch bei anderen soliden Tumoren untersucht wird.

Durch Blockade der auf Lymphozyten lokalisierten CTLA-4-Rezeptoren soll die tumorvermittelte Immuntoleranz, die zur ungehemmten Proliferation von Tumorzellen beiträgt, blockiert werden. Damit verbunden ist eine T-Zellaktivierung die ein Spektrum von Nebenwirkungen hervorruft, die als sog. „immun-related adverse events“ (IRAE) bezeichnet werden. IRAE betreffen auch das endokrine System und führen zu Hypophysitis, Thyreoiditis oder Adrenalitis. Häufig präsentieren sich davon betroffene Patienten mit rel. unspezifischen Symptomen. Insbesondere die unbemerkte und unbehandelte Nebennierenrinden-Insuffizienz kann fatale Folgen haben. Ausgehend von einem Fallbeispiel und der aktuellen Literatur zeigt der folgende Artikel das Spektrum, sowie die zielgerichtete Diagnostik und Therapie von IRAEs unter Ipilimumab.

Abstract

New immune-modulating treatments like the anti-CTLA-4-antibodies-based therapies are increasingly used in medical oncology. The action of Ipilimumab, a monoclonal anti-CTLA-4-antibody used for the treatment of metastasized melanoma and other solid tumors, is well documented. Blocking the CTLA-4-receptors on lymphocytes leads to T-cell acitivation and hence reduction of the tumor-mediated immuntolerance. This mechanism constitutes the basis of the antiproliferative effects but is also responsible for a spectrum of specific adverse events (immune-related adverse events, IRAE). IRAE of the endocrine system comprise hypophysitis, thyroiditis and adrenalitis. Especially adrenal insufficiency can be fatal when not diagnosed and treated. Symptoms often are unspecific and early diagnosis and targeted treatment are crucial. We present a case report and summarize – based upon the current literature – the diagnosis and treatment of endocrinologic IRAEs.

Schüsselwörter

Anti-CTLA-4-Antikörper - Ipilimumab - Immune-Related Adverse Events - Hypophysitis - Thyreoiditis - Adrenalitis

Keywords

anti-CTLA-4-Antibodies - Ipilimumab - immune-related adverse events - hypophysitis - thyroiditis - adrenalitis

• Literatur

• 1 Ascierto PA, Simeone E, Sznol M et al. Clinical experiences with anti-CD137 and anti-PD1 therapeutic antibodies. Semin Oncol 2010; 37: 508-516
• 2 Blansfield JA, Beck KE, Tran K et al. Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer. J Immunother 2005; 28: 593-598
• 3 Carmichael JD. Update on the diagnosis and management of hypophysitis. Curr Opin Endocrinol Diabetes Obes 2012; 19: 314-321
• 4 Carpenter KJ, Murtagh RD, Lilienfeld H et al. Ipilimumab-induced hypophysitis: MR imaging findings. Am J Neuroradiol 2009; 30: 1751-1753
• 5 Caturegli P, Newschaffer C, Olivi A et al. Autoimmune hypophysitis. Endocr Rev 2005; 26: 599-614
• 6 Corsello SM, Barnabei A, Marchetti P et al. Endocrine side effects induced by immune checkpoint inhibitors. J Clin Endocrinol Metab 2013; 98: 1361-1375
• 7 Corsello SM, Salvatori R, Barnabei A et al. Ipilimumab-induced endocrinopathies: when to start corticosteroids (or not). Cancer Chemother Pharmacol 2013; 72: 489-490
• 8 Coursin DB, Wood KE. Corticosteroid supplementation for adrenal insufficiency. JAMA 2002; 287: 236-240
• 9 Di Giacomo AM, Biagioli M, Maio M. The emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indications. Semin Oncol 2010; 37: 499-507
• 10 Dillard T, Yedinak CG, Alumkal J et al. Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes. Pituitary 2010; 13: 29-38
• 11 Dillman RO. Cancer immunotherapy. Cancer Biother Radiopharm 2011; 26: 1-64
• 12 Fassett DR, Couldwell WT. Metastases to the pituitary gland. Neurosurg Focus 2004; 16: E8
• 13 Hodi FS, O’Day SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711-723
• 14 Juszczak A, Gupta A, Karavitaki N et al. Ipilimumab: a novel immunomodulating therapy causing autoimmune hypophysitis: a case report and review. Eur J Endocrinol 2012; 167: 1-5
• 15 Min L, Vaidya A, Becker C. Thyroid autoimmunity and ophthalmopathy related to melanoma biological therapy. Eur J Endocrinol 2011; 164: 303-307
• 16 Min L, Vaidya A, Becker C. Association of ipilimumab therapy for advanced melanoma with secondary adrenal insufficiency. Endocr Pract 2012; 18: 351-355
• 17 Molitch ME, Gillam MP. Lymphocytic hypophysitis. Horm Res 2007; 68 (Suppl. 05) 145-150
• 18 Peggs KS, Quezada SA, Allison JP. Cell intrinsic mechanisms of T-cell inhibition and application to cancer therapy. Immunol Rev 2008; 224: 141-165
• 19 Persani L. Clinical review: Central hypothyroidism: pathogenic, diagnostic, and therapeutic challenges. J Clin Endocrinol Metab 2012; 97: 3068-3078
• 20 Rivera JA. Lymphocytic hypophysitis: disease spectrum and approach to diagnosis and therapy. Pituitary 2006; 9: 35-45
• 21 Torino F, Barnabei A, De Vecchis L et al. Hypophysitis induced by monoclonal antibodies to cytotoxic T lymphocyte antigen 4: challenges from a new cause of a rare disease. Oncologist 2012; 17: 525-535
• 22 Torino F, Barnabei A, Paragliola RM et al. Thyroid as unintended side effect of anticancer drugs. Thyroid 2013;
• 23 van der Hiel B, Blank CU, Haanen JB et al. Detection of early onset of hypophysitis by (18)F-FDG PET-CT in a patient with advanced stage melanoma treated with ipilimumab. Clin Nucl Med 2013; 38: e182-e184
• 24 Warner MH, Beckett GJ. Mechanisms behind the non-thyroidal illness syndrome: an update. J Endocrinol 2010; 205: 1-13
• 25 Weber JS, Kahler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol 2012; 30: 2691-2697